InvestorsHub Logo
Followers 12
Posts 1014
Boards Moderated 0
Alias Born 09/20/2013

Re: None

Wednesday, 12/10/2014 4:31:35 PM

Wednesday, December 10, 2014 4:31:35 PM

Post# of 38634
While we try to make sense of today's trading and what it might forecast- here's a scenario that has been brought up before- but possibly not given enough credibility.

While looking through Della Penna's LinkedIn profile- something new jumped out at me that I hadn't noticed last time I looked it over. https://www.linkedin.com/profile/view?id=37528498&authType=NAME_SEARCH&authToken=K8j5&locale=en_US&trk=tyah&trkInfo=tarId%3A1418246521023%2Ctas%3ADomenic%20Della%20Pen%2Cidx%3A1-2-2

If you look at his endorsements- I find it curiously awesome that 2nd only to leadership- we find "Mergers and Acquisitions". Not surprising for a successful CFO- however the circumstances surrounding his leaving TEVA, without any PR that I can find from them... may indicate something else going on here behind the scenes. Also- the similarly timed release about the 5mg (and possible 40mg) dosage launches of Focalin by Teva seemed conveniently timed. Although I still don't think it's the most likely scenario at this point in time...does anyone else think IPCI might be a real buy-out or acquisition target for Teva? It totally makes sense from a competitive standpoint, and Teva is one of the few companies who probably appreciates the value of the tech and science behind IPCI's products- I guess the question is this- Are Teva's pockets deep enough to afford what Odidi likely wants for this company...that's where I come up doubtful. However a lot of interesting developments in the last couple of months make one wonder....

Your results may vary...